The Long Run with Luke Timmerman

Ep111: Ray Stevens on Structural Biology-Driven Drug Discovery

Mar 14, 2022

01:02:42

Creator website

Highlights

AI Chapters

Episode notes

How to Build Trust in a Bilateral Company?

04:23

How to Get the Most Out of Your Intellectual Property

02:13

What Was So Difficult About GPC Rs?

02:33

Introduction

3min

Ray Stevens, Welcome to the Long Run

2min

What Was It Like Growing Up in Auburn, Main?

2min

Growing Up, What Do You Do for a Living?

2min

What Kind of Student Did You Be?

2min

University of Southern Maine

3min

How Did You Get Into Pharmacology?

3min

Aurkly, I'm a Chemist and I'd Like to Be an Independent Professor

3min

What Was So Difficult About GPC Rs?

3min

10.

Do You Have Any Success With G Protin Coupled Receptors?

3min

11.

Collaboration With Pete Scholtz Was Incredibly Productive

2min

12.

What Kind of Skills Were You Surrounded by at Te Scrips?

2min

13.

How Did You Become a Biotechnologist?

2min

14.

What I Love About Starting Biote Companies

2min

15.

The Long Run Podcast

2min

16.

How Big of a Life Anger Was This for You as a Co-Founder?

3min

17.

Is Small Molecule a Better Modality Than a Biologic?

2min

18.

Drug Discovery Platform - What Are the Biggest Breakthroughs?

2min

19.

Receptos Salgin's Not Going to Do Anything With This.

2min

20.

How Did You See the Potential in China?

4min

21.

You're No Longer a Professor at Us C

2min

22.

How Much of the Language Do You Speak?

3min

23.

How to Build Trust in a Bilateral Company?

4min

24.

How to Get the Most Out of Your Intellectual Property

2min

25.

Biotec - What's Next for Biotec?

2min

26.

The Long Run, a Production Oftier and Report

2min

Ray Stevens, CEO of ShouTi, on structural biology driven drug discovery.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.